Work

Supplementary Tables S1-3 from Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Table 1: Tumor volume measurements during treatment Supplementary Table 2: List of mice with drug-resistant tumors Supplementary Table 3: List of mice that did not develop drug resistance. Tables listing mice used in the therapeutic studies showing tumor volumes and tumor volume changes through treatment.

DOI: 10.1158/1078-0432.22458750.v1

Authors: Valentina Pirazzoli, Deborah Ayeni, Catherine B. Meador, Basavaraju G. Sanganahalli, Fahmeed Hyder, Elisa de Stanchina, Sarah B. Goldberg, William Pao, Katerina Politi

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361918271

Cites:

Cited by:

Related to: 10